KG 005
Alternative Names: KG-005Latest Information Update: 24 Dec 2025
At a glance
- Originator Kaigene
- Class Immunotherapies; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Autoimmune disorders
Most Recent Events
- 03 Dec 2025 Preclinical trials in Autoimmune disorders in USA (Parenteral) prior to December 2025 (Kaigene pipeline, December 2025)